Insider Trading June 24, 2026 10:12 AM

EPR Properties Executive Sale and Q1 2026 Performance Review

Insider transaction analysis and financial results for EPR Properties

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
EPR

Paul Robert Turvey, Senior Vice President and General Counsel at EPR Properties (NYSE:EPR), executed a sale of 6,400 shares on June 23, 2026, valued at $372,480. The transaction, conducted under a pre-established Rule 10b5-1 trading plan adopted on March 24, 2026, occurred within a price range of $58.09 to $58.52, with a weighted average price of $58.20 per share. Following the sale, Turvey retains direct ownership of 46,189 shares. The sale coincides with EPR Properties' strong Q1 2026 financial results, which exceeded Wall Street expectations, and recent analyst upgrades.

EPR Properties Executive Sale and Q1 2026 Performance Review
EPR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Paul Robert Turvey sold 6,400 shares of EPR Properties on June 23, 2026, under a Rule 10b5-1 plan, retaining 46,189 shares.
  • EPR Properties reported Q1 2026 earnings per share of $0.74 and revenue of $181.3 million, exceeding Wall Street expectations.
  • Analysts upgraded EPR Properties' rating and price target, citing strong theater portfolio management and investment activity.

Paul Robert Turvey, Senior Vice President and General Counsel at EPR Properties (NYSE:EPR), executed a sale of 6,400 shares of the company’s common stock on June 23, 2026, totaling $372,480 in value. The transaction was processed at a weighted average price of $58.20 per share, occurring within a price range of $58.09 to $58.52. This sale was facilitated under a Rule 10b5-1 trading plan that Turvey established on March 24, 2026. As of the transaction date, EPR Properties shares were trading at $59.31, approaching its 52-week high of $62.08, with a year-to-date gain of nearly 22%.

Post-transaction, Turvey maintains direct ownership of 46,189 shares in EPR Properties. The Real Estate Investment Trust (REIT) continues to offer a dividend yield of 6.29%, marking 30 consecutive years of dividend payments. According to InvestingPro analysis, EPR Properties appears overvalued at its current price levels. Detailed analysis is available through the comprehensive Pro Research Report, accessible for EPR and over 1,400 US equities.

In recent developments, EPR Properties reported Q1 2026 financial results that surpassed Wall Street expectations. The company posted earnings per share of $0.74, beating the consensus forecast of $0.66, while revenue reached $181.3 million, outperforming the expected $150.34 million. Additionally, EPR Properties announced a monthly cash dividend of $0.31 per common share, resulting in an annualized dividend of $3.72 per share.

At its 2026 Annual Meeting of Shareholders, EPR Properties elected all nominated trustees to serve one-year terms. Citizens upgraded EPR Properties’ stock rating to Market Outperform from Market Perform, citing the company’s management of its theater portfolio and increased investment activity. RBC Capital raised its price target on EPR Properties to $61 from $59, following the company’s first-quarter earnings report. These developments reflect EPR Properties’ ongoing efforts to enhance its financial performance and strategic initiatives.

Risks

  • InvestingPro analysis suggests EPR Properties may be overvalued at current levels, indicating potential downside risk for investors.
  • The reliance on a Rule 10b5-1 plan for insider sales may obscure the true sentiment of executives regarding the stock's future performance.
  • Market volatility and interest rate fluctuations could impact the REIT sector, affecting EPR Properties' financial stability and dividend sustainability.

More from Insider Trading

Vicor Executive Offloads Shares Under Pre-Arranged Plan Jun 24, 2026 Aquestive Therapeutics Director Julie Krop Sells $125k in Stock Jun 24, 2026 ACCESS Newswire Executive Brian Balbirnie Executes $11,725 Stock Divestment Jun 24, 2026 Horizon Kinetics Increases Stake in RENN Fund With $2,079 Share Purchase Jun 24, 2026 UroGen Pharma Insider Sale: CMO Schoenberg Offloads $350K in Shares Amid Patent Victory and Clinical Momentum Jun 24, 2026